DNA methylation profiles in cancer: functions, therapy, and beyond

References

1. 1.↵
   2. Cheng Y,
   3. He C,
   4. Wang M,
   5. Ma X,
   6. Mo F,
   7. Yang S, et al.

   Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019; 4: 62.

   OpenUrl
2. 2.↵
   2. Zhao S,
   3. Allis CD,
   4. Wang GG.

   The language of chromatin modification in human cancers. Nat Rev Cancer. 2021; 21: 413–30.

   OpenUrlCrossRef
3. 3.↵
   2. Hanahan D,
   3. Weinberg RA.

   Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–74.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   2. Chen JJ,
   3. Wang AQ,
   4. Chen QQ.

   DNA methylation assay for colorectal carcinoma. Cancer Biol Med. 2017; 14: 42–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Wang S,
   3. Fu J,
   4. Fang X.

   A novel DNA methylation-related gene signature for the prediction of overall survival and immune characteristics of ovarian cancer patients. J Ovarian Res. 2023; 16: 62.

   OpenUrl
6. 6.↵
   2. Liang WW,
   3. Lu RJ,
   4. Jayasinghe RG,
   5. Foltz SM,
   6. Porta-Pardo E,
   7. Geffen Y, et al.

   Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin. Cancer Cell. 2023; 41: 1567–85.

   OpenUrl
7. 7.↵
   2. Zhao A,
   3. Zhou H,
   4. Yang J,
   5. Li M,
   6. Niu T.

   Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct Target Ther. 2023; 8: 71.

   OpenUrl
8. 8.↵
   2. Zagorac S,
   3. Alcala S,
   4. Fernandez BG,
   5. Bou KT,
   6. Schoenhals M,
   7. Gonzalez-Neira A, et al.

   DNMT1 inhibition reprograms pancreatic cancer stem cells via upregulation of the miR-17-92 cluster. Cancer Res. 2016; 76: 4546–58.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   2. Lee E,
   3. Wang J,
   4. Yumoto K,
   5. Jung Y,
   6. Cackowski FC,
   7. Decker AM, et al.

   DNMT1 regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis. Neoplasia. 2016; 18: 553–66.

   OpenUrlCrossRef
10. 10.↵
    2. Liu R,
    3. Zhao E,
    4. Yu H,
    5. Yuan C,
    6. Abbas MN,
    7. Cui H.

    Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal Transduct Target Ther. 2023; 8: 310.

    OpenUrl
11. 11.↵
    2. Kiyotani K,
    3. Toyoshima Y,
    4. Nakamura Y.

    Personalized immunotherapy in cancer precision medicine. Cancer Biol Med. 2021; 18: 955–65.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Mazor T,
    3. Pankov A,
    4. Song JS,
    5. Costello JF.

    Intratumoral heterogeneity of the epigenome. Cancer Cell. 2016; 29: 440–51.

    OpenUrlCrossRefPubMed
13. 13.↵
    2. Guo H,
    3. Vuille JA,
    4. Wittner BS,
    5. Lachtara EM,
    6. Hou Y,
    7. Lin M, et al.

    DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell. 2023; 186: 2765–82.

    OpenUrl
14. 14.↵
    2. Belk JA,
    3. Daniel B,
    4. Satpathy AT.

    Epigenetic regulation of T cell exhaustion. Nat Immunol. 2022; 23: 848–60.

    OpenUrl
15. 15.↵
    2. Lai SC,
    3. Su YT,
    4. Chi CC,
    5. Kuo YC,
    6. Lee KF,
    7. Wu YC, et al.

    DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res. 2019; 38: 474.

    OpenUrl
16. 16.↵
    2. Stewart ML,
    3. Tamayo P,
    4. Wilson AJ,
    5. Wang S,
    6. Chang YM,
    7. Kim JW, et al.

    KRAS genomic status predicts the sensitivity of ovarian cancer cells to decitabine. Cancer Res. 2015; 75: 2897–906.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    2. Wang N,
    3. Ma T,
    4. Yu B.

    Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023; 8: 69.

    OpenUrl
18. 18.↵
    2. Zhou S,
    3. Ou H,
    4. Wu Y,
    5. Qi D,
    6. Pei X,
    7. Yu X, et al.

    Targeting tumor endothelial cells with methyltransferase inhibitors: mechanisms of action and the potential of combination therapy. Pharmacol Ther. 2023; 247: 108434.
19. 19.↵
    2. Li Y,
    3. Porta-Pardo E,
    4. Tokheim C,
    5. Bailey MH,
    6. Yaron TM,
    7. Stathias V, et al.

    Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell. 2023; 186: 3921–44.

    OpenUrl
20. 20.↵
    2. Geffen Y,
    3. Anand S,
    4. Akiyama Y,
    5. Yaron TM,
    6. Song Y,
    7. Johnson JL, et al.

    Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. 2023; 186: 3945–67.

    OpenUrl